A Randomized Trial of Rosuvastatin in the Prevention

Slides:



Advertisements
Similar presentations
Presenter Disclosure Information Paul M Ridker, MD, FACC Dr Ridker is listed as a co-inventor on patents held by the Brigham and Womens Hospital that relate.
Advertisements

JUPITER ACC March 29, 2009 A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism: The JUPITER Trial Robert Glynn*, Eleanor Danielson,
Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Presenter Disclosure Information Paul M Ridker, MD, FACC Dr Ridker is listed as a co-inventor on patents held by the Brigham and Women’s Hospital that.
Henry C. Ginsberg, MD College of Physicians & Surgeons, Columbia University, New York For The ACCORD Study Group.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
The Definitive Thrombosis Update
CC-1 hsCRP, Inflammation, LDL, and The JUPITER Trial: Rationale, Results, and Public Health Implications Paul M Ridker, MD, MPH Eugene Braunwald Professor.
Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.
Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.
Statins for the Primary Prevention of CVD in Women with Elevated hsCRP or Dyslipidemia: Results from JUPITER and Meta-Analysis of Women from Primary Prevention.
The JUPITER Trial JUPITER AHA November 9, 2008
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
“An Examination of the JUPITER Trial”
Michal Vrablík Centre for Preventive Cardiology 3 rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University in Prague Czech Republic.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]
Antiplatelet Therapy Use and the Risk of Venous Thromboembolic Events in the Double-Blind Raloxifene Use for the Heart (RUTH) Trial C. Duvernoy 1, A. Yeo.
JUPITER AHA November 9, 2008 A Randomized Trial of Rosuvastatin in the Prevention of Cardiovascular Events Among 17,802 Apparently Healthy Men and Women.
Comparison of the Progression of Coronary Atherosclerosis for Two High Efficacy Statin Regimens with Different HDL Effects: SATURN Study Results SJ Nicholls,
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
A Diabetes Outcome Progression Trial
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
BRIAN CLAYTON INTERNAL MEDICINE ADVISOR: ANNA MAE SMITH PRECEPTOR: DR. RAJESH PATEL Evidence Based Medicine Spring 2009.
A Review of – Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Ted Williams Pharm D Candidate Monday Lab.
Tailoring Intervention – Effectively Targeting the High-risk Population Cardiovascular Event Reduction in the Higher-Risk Primary Prevention Population.
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
The Heart Outcomes Prevention Evaluation (HOPE) – 3 Trial
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
JUPITER ACC March 30, 2009 CRP Reduction, LDL Reduction, and Cardiovascular Event Rates After Initiation of Rosuvastatin: The JUPITER Trial Paul Ridker*,
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Title slide.
Should hsCRP be Included in the New Cardiovascular Guidelines?
The relation between venous and arterial thrombosis
Reduction in Total Cardiovascular Events with the PCSK9 Inhibitor Evolocumab in Patients with Cardiovascular Disease in the FOURIER Trial Sabina A. Murphy,
AHA 2017 Residual Inflammatory Risk and Residual Cholesterol Risk:
AIM HIGH Niacin plus Statin to prevent vascular events
HDL cholesterol and cardiovascular risk Epidemiological evidence
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
First time a CETP inhibitor shows reduction of serious CV events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Lipid Lowering Efficacy of Bococizumab Among 4,449 High Risk Patients
The ASSERT Study.
ACC 2018 Orlando, Florida Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes A Pre-Specified Secondary Endpoint from.
ACC 2018 Orlando, Florida Interleukin-1b Inhibition with Canakinumab and Cardiovascular Event Reduction Among Patients with Moderate Chronic Kidney Disease.
ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease Jane Armitage.
Timothy A. Brighton, M. B. , B. S. , John W. Eikelboom, M. B. , B. S
on behalf of the ASCOT Investigators *Imperial College London, UK
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Dabigatran in myocardial injury after noncardiac surgery
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group
Baseline characteristics of HPS participants by prior diabetes
The Hypertension in the Very Elderly Trial (HYVET)
Section 7: Aggressive vs moderate approach to lipid lowering
Dabigatran in myocardial injury after noncardiac surgery
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.
Dabigatran in myocardial injury after noncardiac surgery
Presenter Disclosure Information
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
ACC 2018 Orlando, Florida Interleukin-1b Inhibition with Canakinumab and Cardiovascular Event Reduction Among Patients with Moderate Chronic Kidney Disease.
Presentation transcript:

A Randomized Trial of Rosuvastatin in the Prevention JUPITER ACC March 29, 2009 A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism: The JUPITER Trial Robert Glynn*, Eleanor Danielson, Francisco Fonseca*, Jacques Genest*, Antonio Gotto*, John Kastelein*, Wolfgang Koenig*, Peter Libby*, Alberto Lorenzatti*, Jean MacFadyen, Børge Nordestgaard*, James Shepherd*, James Willerson, and Paul Ridker* on behalf of the JUPITER Trial Study Group An Investigator Initiated Trial Funded by AstraZeneca, USA * These authors have received research grant support and/or consultation fees from one or more statin manufacturers, including Astra-Zeneca. Dr Ridker is a co-inventor on patents held by the Brigham and Women’s Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease that have been licensed to Dade-Behring and AstraZeneca.

Presenter Disclosure Information Robert J Glynn, PhD, ScD; Brigham & Women’s Hospital, Boston, MA The following relationship exists related to this presentation: Research Grant AstraZeneca Significant Level The Brigham & Women’s Hospital holds patents related to the use of inflammatory biomarkers in cardiovascular disease that have been licensed to Dade-Bering and AstraZeneca

JUPITER Timeline JUPITER ACC March 29, 2009 First randomization: March 14, 2003 Last randomization: December 15, 2006 Termination for efficacy: March 30, 2008 Last patient visit: August 20, 2008 Trial results: Primary end point: November 9, 2008 Pre-specified VTE end point: March 29, 2009 hsCRP and LDL reductions and end points: March 30, 2009

Why Pre-specify Incident Venous Thromboembolism? JUPITER Why Pre-specify Incident Venous Thromboembolism? Venous and arterial thrombosis are common, serious, age-related events that often co-occur and share some risk factors Controversies persist regarding the nature and extent of their shared pathways and whether treatments of demonstrated efficacy for one condition have consistent benefits for the primary or secondary prevention of the other Benefits of statins might accrue not only through effects on lipids but also through influence on thrombosis and inflammation. Specifically, statins downregulate the blood coagulation cascade through decreased tissue factor expression, which leads to reduced thrombin formation* *Undas, Brummel-Ziedins, Mann. ATVB 2005;25:287-294

Observational studies of statins & VTE 1st Author Publication Study Adj. RR 95% CI Grady Ann Intern Med 2000 Heart & E/P Replacement 0.5 0.2-0.9 Ray Arch Int Med 2001 Ontario residents 65+ yrs 0.8 0.7-0.9 Yang Br J Clin Pharm 2002 UK database f-up Case-control 1.1 0.3-2.7 0.3-4.3 Doggen J Thromb Haemost 2004 Washington HMO 0.6 0.4-1.1 Lacut Fund Clin Pharm 2004 France, case-control 0.4 0.2-0.8 Smeeth Br J Cl Pharm 2008 1.0 0.9-1.2 Ramcharan J Thromb Haemost 2009 Holland, case-control 0.4-0.6 Sørensen Denmark, case-control 0.7 0.6-0.9 Ischemic stroke top vs bottom quartile: PHS, Framingham, CHS, Honolulu Gussekloo: fatal stroke for CRP of 5-10 mg/L vs those with <5 mg/L NHANES: Risk of stroke for those in the highest tertile of CRP versus those with undetectable CRP levels (>0.55 mg/dL vs  0.21 mg/dL). WHS: Risk of ischemic stroke for those in the highest versus the lowest tertile. ARIC: Risk of ischemic stroke for those in the CDC/AHA defined high risk category (CRP > 3.0 mg/L) versus those in the CDC/AHA low risk category (CRP < 1.0 mg/L). Rotterdam study: top vs bottom quartile for total stroke (similar results for ischemic and hemorrhagic stroke).

JUPITER Why Pre-specify Incident Venous Thromboembolism? Observational Evidence: In non-randomized cohort and case-control studies and registries, statins have often, but not always, been associated with reduced risk of VTE. These studies cannot exclude indication bias. Many included prevalent statin users, and poor health affects the decision to initiate and persist in therapy. They also did not consider the possibility that the reduction in VTE events is secondary to a statin-induced reduction in arterial hospitalizations. Similar evidence from observational studies indicated benefits for statins on mortality in heart failure, but trials (CORONA, GISSI) refuted this hypothesis Clear need for a prospective randomized trial

JUPITER Inclusion and Exclusion Criteria, Study Flow Men > 50 years Ridker et al NEJM 2008 89,890 Screened 89,863 Screened Reason for Exclusion (%) LDL-C > 130 mg/dL 53 hsCRP < 2.0 mg/L 37 Withdrew Consent 4 Diabetes 1 Hypothyroid <1 Liver Disease <1 TG > 500 mg/dL <1 Age out of range <1 Current Use of HRT <1 Cancer <1 Poor Compliance/Other 3 Reason for Exclusion (%) LDL > 130 mg/dL 52 hsCRP < 2.0 mg/L 36 Withdrew Consent 5 Diabetes 1 Hypothyroid <1 Liver Disease <1 TG > 500 mg/dL <1 Age out of range <1 Current Use of HRT <1 Cancer <1 Poor Compliance/Other 3 Men > 50 years Women > 60 years No CVD, No DM LDL < 130 mg/dL hsCRP > 2 mg/L 4 week Placebo Run-In 17,802 Randomized 17,802 Randomized 8,901 Assigned to Rosuvastatin 20 mg 8,901 Assigned to Rosuvastatin 20 mg 8,901 Assigned to Placebo 8,901 Assigned to Placebo 8,600 Completed Study 120 Lost to follow-up 8,857 Completed Study 44 Lost to follow-up 8,864 Completed Study 37 Lost to follow-up 8,600 Completed Study 120 Lost to follow-up 8,901 Included in Efficacy and Safety Analyses 8,901 Included in Efficacy and Safety Analyses 8,901 Included in Efficacy and Safety Analyses 8,901 Included in Efficacy and Safety Analyses

JUPITER Symptomatic VTE Symptomatic venous thromboembolism was a pre-specified secondary end point Upon identification of a new VTE case, site investigators indicated the source of confirmation (venous ultrasonogram or venogram for DVT; angiogram, CT scan, or ventilation-perfusion scan for PE) Initiation and indication for anticoagulation therapy also noted Unprovoked VTE: no trauma, hospitalization, or surgery within 3 months before diagnosis, and no malignancy diagnosed before or up to 3 months after the VTE Unprovoked and provoked VTE, pulmonary embolism and deep vein thrombosis alone were tertiary end points.

JUPITER VTE analysis Primary efficacy analyses counted all events diagnosed by March 30, 2008 according to the intention to treat principle Safety analyses also included additional events before the closeout visit and unblinding Competing risks analyses compared effects of rosuvastatin on first VTE versus first primary cardiovascular event Estimates of net clinical benefits considered the impact on the number needed to treat (NNT) of inclusion of VTE in a composite with the primary cardiovascular event, and also with total mortality

Baseline Clinical Characteristics JUPITER Baseline Clinical Characteristics Glynn et al NEJM 2009 Rosuvastatin Placebo (N = 8901) (n = 8901) Age, years (IQR) 66 (60-71) 66 (60-71) Female, N (%) 3,426 (38) 3,375 (38) Ethnicity, N (%) Caucasian 6,358 (71) 6,325 (71) Black 1,100 (12) 1,124 (13) Hispanic 1,121 (13) 1,140 (13) Body mass index ≥ 30 kg/m2, N (%) 3,338 (38) 3,336 (38) Waist circumference (cm) ≥100 (men), ≥95 (women), N (%) 4,503 (51) 4,546 (52) Smoker, N (%) 1,400 (16) 1,420 (16) Metabolic Syndrome, N (%) 3,652 (41) 3,723 (42) hsCRP≥5 mg/L, N (%) 3,618 (41) 3,726 (42) LDL>100 mg/dL, N (%) 5,781 (65) 5,747 (65) HDL<40 (men), <50 (women), N (%) 2,833 (32) 2,856 (32) All values are median (interquartile range) or N (%)

Total Venous Thromboembolism JUPITER Total Venous Thromboembolism Glynn et al NEJM 2009 HR 0.57, 95%CI 0.37-0.86 P= 0.007 0.025 0.020 Placebo 60 / 8901 0.015 - 43 % Cumulative Incidence 0.010 Rosuvastatin 34 / 8901 0.005 0.000 1 2 3 4 Follow-up (years) Number at Risk Rosuvastatin 8,901 8,648 8,447 6,575 3,927 1,986 1,376 1,003 548 161 Placebo 8,901 8,652 8,417 6,574 3,943 2,012 1,381 993 556 182

Occurrence of VTE: Primary efficacy analysis JUPITER Occurrence of VTE: Primary efficacy analysis Glynn et al NEJM 2009 All cases identified by March 30, 2008 Endpoint Rosuvastatin Placebo HR 95%CI P Any VTE 34 60 0.57 0.37-0.86 0.007 Unprovoked VTE 19 31 0.61 0.35-1.09 0.09 Provoked VTE 15 29 0.52 0.28-0.96 0.03 Pulmonary embolism 17 22 0.77 0.41-1.45 0.42 DVT only 17 38 0.45 0.25-0.79 0.004

Venous Thromboembolism – Unprovoked vs Provoked JUPITER Venous Thromboembolism – Unprovoked vs Provoked Unprovoked Venous Thromboembolism Provoked Venous Thromboembolism HR 0.61, 95% CI 0.35-1.09 P= 0.09 HR 0.52, 95% CI 0.28-0.96 P= 0.03 0.020 0.020 0.015 0.015 Cumulative Incidence Cumulative Incidence 0.010 Placebo 0.010 Placebo 0.005 0.005 Rosuvastatin Rosuvastatin 0.000 0.000 1 2 3 4 1 2 3 4 Follow-up (years) Follow-up (years) Clear clinical benefit in the absence of any bleeding hazard (hemmorrhagic events: rosuvastatin 258, placebo 275, P=0.45)

Total Venous Thromboembolism – Subgroup Analysis I JUPITER Total Venous Thromboembolism – Subgroup Analysis I Incidence Rates N Events (Placebo) Men 11,001 66 0.37 Women 6,801 28 0.24 Age 50-59 yr 3,689 17 0.24 Age 60-69 yr 8,418 37 0.30 Age > 70 yr 5,695 40 0.41 Caucasian 12,683 86 0.39 Black, Hispanic, Other 5,117 8 0.11 BMI <25.0 kg/m 2 4,073 15 0.20 BMI 25.0-29.9 kg/m 2 7,009 32 0.30 BMI > 30.0 kg/m 2 6,674 46 0.40 Waist Circumference(cm) Men<100/Women<95 8,586 34 0.21 Men > 100/Women > 95 9,049 57 0.41 Metabolic Syndrome 7,373 32 0.29 No Metabolic Syndrome 10,296 60 0.34 Smoker 2,820 13 0.22 Non-Smoker 14,975 81 0.34 All Participants 17,802 94 0.32 0.20 0.5 1.0 2.0 4.0 Rosuvastatin Superior Rosuvastatin Inferior

Total Venous Thromboembolism – Subgroup Analysis II JUPITER Total Venous Thromboembolism – Subgroup Analysis II # of Incidence Rates N Events (Placebo) LDLC < 100 mg/dL 6,269 33 0.30 LDLC > 100 mg/dL 11,528 61 0.33 HDLC (mg/dL) Men<40, Women<50 5,689 26 0.30 Men > 40, Women > 50 12,112 68 0.33 Triglycerides<150 mg/dL 11,965 66 0.32 Triglycerides > 150 mg/dL 5,836 28 0.32 hsCRP<5 mg/L 10,458 49 0.27 hsCRP > 5 mg/L 7,344 45 0.39 Time of event < 24 Months 17,802 70 0.28 Time of event>24 Months 7,870 24 0.53 All Participants 17,802 94 0.32 0.20 0.5 1.0 2.0 4.0 Rosuvastatin Superior Rosuvastatin Inferior

Occurrence of VTE: Safety analysis JUPITER Occurrence of VTE: Safety analysis Glynn et al NEJM 2009 All cases identified by final closeout visit and unblinding Endpoint Rosuvastatin Placebo HR 95%CI P Any VTE 35 64 0.55 0.36-0.82 0.003 Unprovoked VTE 20 34 0.59 0.34-1.02 0.06 Provoked VTE 15 30 0.50 0.27-0.93 0.02 Pulmonary embolism 17 24 0.71 0.38-1.32 0.27 DVT only 18 40 0.45 0.26-0.78 0.003

Occurrence of VTE, CVD, and death JUPITER Occurrence of VTE, CVD, and death Glynn et al NEJM 2009 Endpoint Rosuvastatin Placebo HR 95%CI P VTE without prior CVD 32 56 0.57 0.37-0.88 0.009 CVD without prior VTE 141 249 0.56 0.46-0.69 <0.001 VTE after CVD 2 4 0.98 0.18-5.34 0.98 First CVD or VTE 173 305 0.56 0.47-0.68 <0.001 Death after VTE 7 14 0.88 0.35-2.18 0.78 First CVD, VTE or death 320 483 0.66 0.57-0.76 <0.001

JUPITER Primary Trial Endpoint : MI, Stroke, UA/Revascularization, CV Death HR 0.56, 95% CI 0.46-0.69 P < 0.00001 Placebo 251 / 8901 0.08 Number Needed to Treat (NNT5) = 25 0.06 109 Fewer Events Cumulative Incidence 0.04 Rosuvastatin 142 / 8901 0.02 0.00 1 2 3 4 Follow-up (years) Number at Risk Rosuvastatin 8,901 8,631 8,412 6,540 3,893 1,958 1,353 983 544 157 Placebo 8,901 8,621 8,353 6,508 3,872 1,963 1,333 955 534 174

JUPITER VTE + Primary Trial Endpoint HR 0.56, 95% CI 0.47-0.68 P < 0.00001 Placebo 305 / 8901 0.10 Number Needed to Treat (NNT5) = 21 0.08 132 Fewer Events 0.06 Cumulative Incidence 0.04 Rosuvastatin 173 / 8901 0.02 0.00 1 2 3 4 Follow-up (years) Number at Risk Rosuvastatin 8,901 8,624 8,400 6,525 3,880 1,951 1,348 979 536 157 Placebo 8,901 8,612 8,338 6,486 3,854 1,949 1,320 945 525 170

JUPITER VTE + Primary Trial Endpoint + Total Mortality HR 0.66, 95% CI 0.57-0.76 P < 0.00001 Placebo 483 / 8901 0.14 0.12 Number Needed to Treat (NNT5) = 18 0.10 163 Fewer Events 0.08 Cumulative Incidence 0.06 0.04 Rosuvastatin 320 / 8901 0.02 0.00 1 2 3 4 Follow-up (years) Number at Risk Rosuvastatin 8,901 8,624 8,400 6,525 3,880 1,951 1,348 979 536 157 Placebo 8,901 8,612 8,338 6,486 3,854 1,949 1,320 945 525 170

JUPITER VTE in JUPITER: Conclusions VTE is a serious event that occurred about as often as MI and stroke in the JUPITER study Rosuvastatin was associated with a significant 43 percent reduction in risk of VTE with no increase in bleeding. This benefit was comparable in magnitude and independent of the effect on arterial events Widening the treatment target to include prevention of VTE and death in addition to arterial thrombosis increases the estimated benefit of statin use